AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04160065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFx-Hu2.0
Description: The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses.
Study NCT04230603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging
Description: Photos were taken with the hyperspectral camera of the human tissue
Study NCT02759640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Description: HS-10241 is administered orally starting at 100 mg/day.
Study NCT03776279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
Study NCT00453687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: investigational drug
Study NCT01299584 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Description: Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT00896831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ornithine-L-aspartate
Description: L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
Study NCT00896831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: 5 g (1 sachet) three times per day for 60 days
Study NCT04000113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: low level laser emission on specific acupuncture points
Study NCT04000113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser
Study NCT01277029 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Psychopathology, personality traits of patients with lower urinary tract symptoms
Study NCT02531685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.
Study NCT04230603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lactate acid measurement
Description: At the marked regions of the specimen, a lactate acid measurement was performed.
Study NCT04230603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pathological examination
Description: At the marked regions of the specimen, the pathological examination was performed.
Study NCT02764047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus 10⁹, B. lactis 10⁹
Study NCT02531685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
Study NCT01757132 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Miniature Telescope
Description: Device - Implantable Miniature Telescope
Study NCT03076463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GRAPOM
Description: The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
Study NCT00381212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
Study NCT02764047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus 10⁹, B. lactis 10⁹
Study NCT00758888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic Blocking
Description: Place the blocks under the pelvis for 2 minutes
Study NCT00758888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanter Belt
Description: Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
Study NCT00758888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blocking Sham
Description: Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
Study NCT00512434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis
Description: Nail or external fixator Intervention 'Osteosynthesis'
Study NCT00512434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: Nail or external fixator Intervention 'Osteosynthesis'
Study NCT01903226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity training
Study NCT01903226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Study NCT00958841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
Study NCT01125514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg tablet
Study NCT01125514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg
Description: Furosemide 60 mg commercially-available tablets
Study NCT03019380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: removing cerumen from external ear (Wondertip)
Description: The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
Study NCT02693067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose bengal disodium
Description: Percutaneous intralesional injection to NET tumor
Study NCT01125514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Matching placebo for aliskiren 150 mg and 300 mg
Study NCT01125514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet
Study NCT03325491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
Study NCT03325491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
Study NCT00858364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered subcutaneously once every 3 weeks
Study NCT00858364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once every 3 weeks
Study NCT01729442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shear-wave ultrasound elastography (SWUE)
Study NCT02680990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band Together
Description: Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
Study NCT02680990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Education
Description: Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
Study NCT03980808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Sign Language-Accessible Diabetes Education
Description: Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
Study NCT03980808 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: Non-health related video approximately the same length as ASL-ADE.
Study NCT03914638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol 4Mg Tablet
Description: Salbutamol 4 mg, three times daily
Study NCT03914638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, three times daily
Study NCT01249027 — intervention group
Intervention type: DEVICE
Intervention: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Description: Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
Study NCT03014011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypoglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
Study NCT03014011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Euglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
Study NCT01203696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: For patient with suboptimal angina control: oral 2.5-10mg daily
Study NCT01203696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: For patient with suboptimal BP control: 2.5-10mg daily po
Study NCT02253264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT04764045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
Study NCT04764045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
Study NCT02646085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 Methionine positron emission tomography
Description: diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
Study NCT03922685 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
Study NCT03922685 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
Study NCT03539510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HF-ACP Website
Description: Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
Study NCT05840445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinum toxin A
Description: Intramuscular application of onabotulinum toxin-A in the upper facial third.
Study NCT05840445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prabotulinumtoxin A
Description: Intramuscular application of prabotulinum toxin-A in the upper facial third.
Study NCT02679846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized protocol
Description: The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
Study NCT03635723 — intervention group
Intervention type: DEVICE
Intervention: Activity monitor
Description: Technology allowing measurement of physical activity
Study NCT01113099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: Education of physicians by pharmacists regarding indications for statins in diabetic patients
Study NCT03761316 — intervention group
Intervention type: OTHER
Intervention: interview regarding goals
Description: interview regarding goals
Study NCT03189459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program
Description: RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
Study NCT03189459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Mentorship Program
Description: Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor
Study NCT04278859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Study NCT01756378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: joint mobilization with movement
Study NCT01756378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: I.R, stretching exercises, strengthen exercises
Study NCT01756378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: I.R, stretching exercises, strengthen exercises
Study NCT01215201 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and Root Planing
Description: Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
Study NCT01215201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser + Scaling and Root Planing
Description: First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
Study NCT01576614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Remote physician rounding
Description: Use of Remote physician rounding using Remote Telepresence Robotics
Study NCT00924898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz, emtricitabine, and tenofovir
Description: Once daily ART with emtricitabine, tenofovir DF and efavirenz
Study NCT04447729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fremanezumab
Description: Two doses, each dose consists of 4 injections with prefilled syringes
Study NCT01635088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate 220
Description: dry powder inhaler QD for 28-43 days
Study NCT01635088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KoKo Spirometry
Study NCT01635088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate 440
Description: dry powder inhaler QD for 28-43 days
Study NCT04642313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
Study NCT04642313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
Study NCT00922753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VS
Description: Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
Study NCT01635088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillometry
Study NCT04386785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins
Description: The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
Study NCT00922753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI-4/PEEP-4
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
Study NCT04400994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes
Study NCT04400994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes
Study NCT04400994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour
Study NCT01824017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Study NCT05302011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg i.v. day 1-22-43-64
Study NCT05302011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
Study NCT05302011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 i.v. day 1-22-43-64
Study NCT01052948 — intervention group
Intervention type: OTHER
Intervention: Retrospective study-
Study NCT02153918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.